Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles

Inclusion Criteria: * Adult females or males, aged 25 to 70 years; * Subjects must be seeking treatment with Juvéderm Ultra and CosmoDerm 1 injections for vertical lip rhytids or radial cheek lines; * Subjects must have one or more moderate to severe vertical lip rhytids and/or moderate to severe radial cheek lines based on the physician evaluator assessment (0-3 scale); * Women must either be of non-childbearing potential (i.e., surgically sterilized or post-menopausal) or if of childbearing potential, must not be pregnant (as documented by a negative urine pregnancy test at the baseline examination) or lactating and must be practicing a medically acceptable method of birth control; * Subjects must be willing and able to provide written informed consent; * Subjects must be willing and able to follow the procedures outlined in this protocol. Exclusion Criteria: * Female subjects who are pregnant (positive urine pregnancy test) or who have an infant they are breast-feeding or who are of childbearing potential and not practicing a reliable method of birth control; * Previous Botox treatment to the lower two-thirds of the face within the past 6 months for subjects who will have injections into their radial cheek lines. Note: this exclusion criterion does not apply to subjects who only will have injections into lip rhytids unless the previous Botox treatment was administered within the past 6 months to the upper lip region; * Previous semipermanent injectable filler therapy to the mid-lower face within the past year or any prior history of permanent filler therapy injection to the mid-lower face; * Prior cosmetic procedures (i.e., facelift, etc.) or visible scars that may affect evaluation of response and/or quality of photography in the opinion of the investigator; * Known allergy or sensitivity to any of the treatment injections or their components, including known or suspected lidocaine hypersensitivity; * Known severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; * Subjects with an infection at an injection site or systemic infection (in this case, postpone study entry until one week following recovery); * Subjects requiring treatment with major anticoagulants (such as Coumadin) or antiplatelets (such as Plavix) during the study; low-dose aspirin treatment or antiinflammatory medication with potential anticoagulant or antiplatelet effect may be allowed at the investigator's discretion; * Concurrent participation in an investigational drug or device study or participation within 30 days of study start; * Subjects are not to undergo any additional cosmetic procedures during the study period; * Subjects are not to change use of any facial products up to 6 months prior to enrollment and during study period; * Subjects with a history of poor cooperation, non-compliance with medical treatment, or unreliability.